KOSPIBiotech & Pharma185750

Chong Kun Dang Pharmaceutical

₩61,000▼ 0.81%2026-11-18 close
Market Cap
₩842B
Turnover
₩500M
Volume
7.6K
Shares out.
13.8M
PER
10.3×
PBR
0.8×
EPS
₩5,935
Dividend Yield
0.82%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩500 per share · Prices as of the 2026-11-18 close

01

Report overview

Imported-Product Growth, Profit Recovery Still Pending

Revenue reached the highest level of the 2022 to 2025 period, but the operating margin has fallen from its 2023 peak to the 4% range, and the pipeline and R&D spending are now the variables that may shape the next phase.

  1. 1

    Revenue in 2025 was KRW 1.69 trillion, the largest year of 2022 to 2025, while operating profit fell to KRW 80.6 billion, declining for two consecutive years from 2024 to 2025.

  2. 2

    The operating margin dropped from 14.8% in 2023 to 4.8% in 2025, and rising cost of sales on imported products and higher R&D expenses are cited as the main background.

  3. 3

    Operating profit of KRW 14.1 billion in the first quarter of 2026 marked the low point, followed by increases in the second and third quarters of 2026.

  4. 4

    Novartis is running a Phase 2 trial of CKD-510, CKD-703 has entered Phase 1/2a in the United States, and KRW 392.5 billion has been approved for the Baegot bio complex investment.

  5. 5

    The debt-to-equity ratio rose to 78.9% at the end of 2025 from 62.7% in 2024, and the research complex investment and expanded R&D are cited as factors that could add to financial pressure.

02

Business structure

Chong Kun Dang Pharmaceutical is a domestic pharmaceutical company centered on prescription drugs, selling both its own products and externally licensed products. Its own products include the anticancer drug Campto Bell, the diabetes treatment Dubie, and the biosimilars Nesbel and Lucentis-biosimilar Lucenvis.

Recent revenue growth has been led by externally sourced products.

Wegovy, the obesity treatment, is a flagship item for which Chong Kun Dang handles domestic distribution and sales, and Pexuclu for reflux disease, Godex for liver disease, Prolia for osteoporosis, and Eylea for macular degeneration are also cited as licensed products.

These products fall under merchandise sales with higher cost ratios than the company's own products, so profit margins do not rise as quickly as sales grow.

The company previously saw a revenue gap when the co-marketing contract for the reflux drug Kcab ended, and it filled that gap with licensed products such as Wegovy. Growth built on licensed products depends on the strategy changes of the outside companies that hold the rights.

On the R&D side, Achela, a drug development subsidiary established in 2025, handles clinical trials and technology exports, while Neurateon, a research subsidiary, handles platform research. Listed peers in the same industry include Yuhan, Hanmi Pharm, and SAM Chun Dang Pharm.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩429.8B₩21B4.9%
2025Q4₩426.8B₩23.5B5.5%
2026Q1₩447.8B₩14.1B3.1%
2026Q2₩478.5B₩18.6B3.9%
2026Q3₩434.3B₩22B5.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.5T₩109.9B₩81B7.4%13.0%81.1%
2023₩1.7T₩246.6B₩212.5B14.8%26.1%71.9%
2024₩1.6T₩99.5B₩109.1B6.3%12.2%62.7%
2025₩1.7T₩80.6B₩77.5B4.8%7.7%78.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue moved from KRW 1.49 trillion in 2022 to KRW 1.67 trillion in 2023 (up 12.2% year on year), KRW 1.59 trillion in 2024 (down 5.0%), and KRW 1.69 trillion in 2025 (up 6.7%), with 2025 the largest year of 2022 to 2025.

Operating profit went from KRW 109.9 billion in 2022 to a peak of KRW 246.6 billion in 2023 (up 124.4%), then to KRW 99.5 billion in 2024 (down 59.7%) and KRW 80.6 billion in 2025 (down 19.0%), declining for two consecutive years.

The operating margin moved from 7.4% in 2022 to 14.8% in 2023, 6.3% in 2024 and 4.8% in 2025. Revenue fell in 2024 and rose in 2025, but the margin stayed at a low level after 2024.

Net profit attributable to controlling shareholders went from KRW 212.5 billion in 2023 to KRW 109.1 billion in 2024 (down 48.7%) and KRW 77.5 billion in 2025 (down 28.9%), also declining for two consecutive years. Net income including non-controlling interests was KRW 77.8 billion in 2025.

In a February 2, 2026 disclosure, the company attributed the 2025 profit decline to higher selling, general and administrative and R&D expenses, along with a base effect from a one-time corporate tax refund in the prior year. The debt-to-equity ratio rose from 62.7% in 2024 to 78.9% in 2025.

At the end of 2025, total equity was KRW 1.01 trillion, equity attributable to controlling shareholders was KRW 1 trillion, and total liabilities were KRW 793.9 billion.

Operating cash flow was KRW 67.7 billion in 2022, KRW 318.2 billion in 2023, KRW 64.3 billion in 2024 and KRW 67.4 billion in 2025, so apart from 2023 it has stayed in the tens of billions of won range.

On a quarterly basis, first-quarter 2026 revenue was KRW 447.8 billion and operating profit was KRW 14.1 billion, down 40.0% from the prior quarter, marking the low point. Second-quarter revenue was KRW 478.5 billion (up 6.9% quarter on quarter) and operating profit was KRW 18.6 billion (up 32.1%).

Third-quarter revenue was KRW 434.3 billion (down 9.2% quarter on quarter, up 1.0% year on year) and operating profit was KRW 22 billion (up 5.1% year on year). Operating profit has risen for two consecutive quarters from the second quarter to the third quarter of 2026.

Net profit attributable to controlling shareholders for the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totals KRW 78.2 billion.

R&D spending was KRW 49.99 billion in the first quarter of 2026 per the quarterly report, equal to 11.17% of revenue, and according to a 2026 press report first-half R&D spending reached KRW 113.5 billion, up 36.6% year on year.

05

Industry analysis

In the first half of 2026 the KOSPI topped the 6000 level, but the rise was concentrated in large semiconductor and AI-related stocks, leaving pharmaceutical and biotech shares without a clear rebound, according to a press report.

Across the domestic pharmaceutical industry, a pattern is commonly observed in which expanding licensed products lifts revenue while higher cost ratios can reduce operating profit.

On the policy side, the government is tightening the criteria for the innovative pharmaceutical company certification, raising the R&D investment ratio requirement for companies with revenue above KRW 100 billion from 5% to 7%, with implementation scheduled for the second half of 2029.

Chong Kun Dang chose to split its R&D organization by function: Neurateon handles research and platform technology upgrades, while Achela handles clinical development and technology exports for core pipeline assets such as CKD-508 for dyslipidemia, CKD-514 for obesity and diabetes, and CKD-513 for neurological disease.

Some companies in the industry have moved to fold R&D subsidiaries back into the parent, so the separated structure is a different choice. On the biosimilar side, the launch of Nesbel in Korea and Japan and the settling of Lucenvis in the market are cited as achievements.

From a demand-cycle perspective, the company is in a phase where growth from licensed products overlaps with a wait for results from its own drug candidates. Compared with listed peers that have their own new-drug pipelines, Chong Kun Dang's pipeline results remain at the clinical stage.

06

Outlook

One outlook on record comes from DS Investment, which published a report on May 26, 2026 projecting Chong Kun Dang's 2026 standalone revenue at KRW 1.8833 trillion, up 12% from the prior year, with operating profit at KRW 78 billion, down 2.7%, and an operating margin of 4.1%.

The report expected Wegovy to keep quarterly sales near KRW 50 billion and drive top-line growth, but it assessed 2026 as a year of earnings stabilization rather than a full profit-growth phase because of higher cost ratios from merchandise sales.

That forecast was prepared before the second-quarter preliminary results were released.

The key pipeline event is the Phase 2 trial of CKD-510, which Novartis develops under the name PKN605 and which is specified for atrial fibrillation; reports differ on the completion date, with one citing a September 2026 target and another expecting completion in 2027, and interim data timing also varies by report.

For the ADC anticancer drug CKD-703, first patient enrollment began in the United States in April 2026, and the trial is running at 12 US clinical sites.

ACL-508 for dyslipidemia released Phase 1 results in June 2026, and ACL-513 for neurodegenerative disease announced nonclinical results in the same month, with the company targeting entry into Phase 1 for ACL-513 by late 2026.

On facilities, Chong Kun Dang's board decided on June 11, 2026 to invest KRW 392.5 billion in building the Baegot bio complex in Siheung, with the investment period running through August 31, 2028, while some reports present the overall complex scale as KRW 2.2 trillion. The complex is planned to include research and pilot-production centers for biopharmaceutical development.

07

Valuation

PER
10.3×
PBR
0.8×
ROE
7.9%
EPS
₩5,935
BPS
₩78,089
Dividend per share
₩500

The price-to-book ratio is below 1x, meaning the share price sits under book value per share.

Earnings-based multiples are calculated on net profit attributable to controlling shareholders of KRW 78.2 billion over the last four quarters, so the multiple shifts considerably with the pace of profit recovery even at the same share price.

Against the 2023 operating profit peak, current earnings are lower, and trading below net asset value forms one side of how the market is currently assessing the stock. The dividend yield is below the industry average.

The market may be weighting pipeline value more heavily than current earnings, and some analysts argue that long-term corporate value will depend on the global clinical progress of CKD-510 and whether later assets are out-licensed.

If growth from licensed products continues without flowing through to profit, the multiple will be more sensitive to whether margins improve. The interpretation of valuation therefore depends on two variables: profit recovery and the clinical results of the pipeline.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Revenue growth led by licensed products

Revenue rose 6.7% to KRW 1.69 trillion in 2025, and second-quarter 2026 revenue reached KRW 478.5 billion, up 6.9% from the prior quarter. Licensed products such as Wegovy, Pexuclu and Godex are supporting the top line.

Third-quarter 2026 revenue also rose 1.0% year on year, showing that growth has continued at the quarterly level. Profit contribution, however, has not kept pace with that growth.

Milestone structure of the Novartis licensing deal

CKD-510 was licensed to Novartis in November 2023, with an upfront payment of about KRW 106.1 billion and staged milestones of up to about KRW 1.62 trillion reported. Novartis is running a Phase 2 trial in atrial fibrillation. Chong Kun Dang received a milestone of about USD 5 million upon entry into Phase 2. Further milestones and royalties after commercialization remain possible as the trial advances.

R&D restructuring and entry into ADC clinical trials

Chong Kun Dang separated research from development and commercialization, assigning the former to Neurateon and the latter to Achela. The ADC anticancer drug CKD-703 began first patient enrollment in the United States in April 2026 after FDA clearance of its clinical trial application.

In June 2026 the board approved a KRW 392.5 billion investment in the Baegot bio complex. Expanding the research base could translate into corporate value if clinical results follow.

09

Bear factors

Declining operating margin

The operating margin fell from 14.8% in 2023 to 4.8% in 2025. Operating profit declined for two consecutive years in 2024 and 2025. First-quarter 2026 operating profit of KRW 14.1 billion was down 40.0% from the prior quarter, marking the low point. Rising revenue without matching profit growth is the strongest bear argument.

Cost ratios and R&D burden

A rising share of merchandise sales has raised the cost ratio. First-half 2026 R&D spending, per a press report, reached KRW 113.5 billion, up 36.6% year on year. First-quarter 2026 R&D spending was KRW 49.99 billion per the quarterly report, equal to 11.17% of revenue.

If capitalized development assets lose their commercial viability after a clinical halt, impairment losses could increase earnings volatility.

Dependence on licensed products and rights risk

The company previously experienced a revenue gap after the co-marketing contract for Kcab ended. Licensed products such as Wegovy are subject to strategy changes at the outside companies that hold the rights. The debt-to-equity ratio at the end of 2025 was 78.9%, up from 62.7% in 2024.

If dependence on outside products grows while financial headroom remains limited, the room to respond to rights changes narrows.

10

Risk factors

Clinical and licensing timelines

Reports differ on when Novartis's Phase 2 trial of CKD-510 will end, with one citing a September 2026 target and another expecting completion in 2027. Pipeline value depends on clinical results, and a halt or delay would also postpone milestone inflows.

Certification and policy regulation

The government plans to raise the R&D investment ratio for companies with revenue above KRW 100 billion from 5% to 7%, starting in the second half of 2029. Chong Kun Dang was confirmed to have been excluded from a past re-certification review and is reported to be preparing to reapply in the second half of 2026. The MFDS efficacy review of Gliatilin is also cited as a variable that could affect revenue.

Financial and investment burden

Total liabilities at the end of 2025 were KRW 793.9 billion, and the debt-to-equity ratio rose to 78.9% from 62.7% in 2024. The Baegot complex investment is KRW 392.5 billion, with an investment period running through August 31, 2028.

Operating cash flow was KRW 67.4 billion in 2025, well below KRW 318.2 billion in 2023, which may limit how much large investment and R&D can be funded from internal cash.

11

What to watch next

  1. Early February 2027

    The likely timing of the 2026 annual preliminary results, to be compared with the 4.8% operating margin of 2025 to check how cost ratios on licensed products and R&D spending are reflected in profit.

  2. End of March 2027

    The filing of the 2026 annual business report, the next regular disclosure, where confirmed full-year financials, the debt-to-equity ratio (78.9% in 2025) and operating cash flow can be checked.

  3. Second half of 2026 (per press reports)

    Whether Chong Kun Dang reapplies for innovative pharmaceutical company certification and the outcome, which connects to its capacity to meet the tighter R&D investment ratio.

  4. Second half of 2026 (per press reports)

    The MFDS efficacy review result for Gliatilin, which could affect prescriptions and sales of the product.

  5. Timing undetermined (reports differ)

    Whether Novartis releases interim Phase 2 data for CKD-510, which would bear directly on additional milestone prospects and platform valuation.

  6. August 31, 2028

    The end of the investment period for the Baegot bio complex, the point at which progress in capital deployment and any increase in the share of own products can be checked.

12

Overall view

Chong Kun Dang's 2025 revenue of KRW 1.69 trillion was the largest year of 2022 to 2025, but operating profit fell to KRW 80.6 billion and declined for two consecutive years from 2024. The operating margin dropped from 14.8% in 2023 to 4.8% in 2025.

First-quarter 2026 operating profit of KRW 14.1 billion marked the low, followed by increases in the second and third quarters. Licensed products such as Wegovy are driving top-line growth, while higher cost ratios and R&D spending are slowing profit recovery.

On the pipeline, Novartis's Phase 2 trial of CKD-510 and the US trial of CKD-703 remain the key variables, and reports differ on when clinical results and milestone inflows will arrive.

On the financial side, the debt-to-equity ratio rose to 78.9% at the end of 2025, and the KRW 392.5 billion Baegot investment runs through August 2028.

Strengths include licensed-product-led growth, the milestone structure of the technology deal, and the R&D restructuring, while weaknesses include the lower operating margin, R&D burden and rights-related risk. The weight of these factors is likely to shift with the pace of profit recovery and clinical outcomes.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. moneytoring.ai
  2. x.com
  3. comp.wisereport.co.kr
  4. srtimes.kr
  5. huffingtonpost.kr
  6. m.news.nate.com
  7. biz.newdaily.co.kr
  8. medipharmhealth.co.kr
  9. kpanews.co.kr
  10. g-enews.com
  11. hankyung.com
  12. the-pr.co.kr
  13. asiatime.co.kr
  14. mediapen.com
  15. lkp.news
  16. news.nate.com
  17. m.news.nate.com
  18. ncbi.nlm.nih.gov

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis